Comparative Pharmacology
Head-to-head clinical analysis: VYKAT XR versus VYVANSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VYKAT XR versus VYVANSE.
VYKAT XR vs VYVANSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VYKAT XR is a fixed-dose combination of amphetamine and dextroamphetamine, which are central nervous system (CNS) stimulants. They increase the synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting their release from presynaptic neurons.
Lisdexamfetamine is a prodrug of dextroamphetamine, which increases synaptic concentrations of dopamine and norepinephrine by blocking their reuptake and reversing the direction of transport via the dopamine and norepinephrine transporters.
100 mg orally once daily with or without food, administered in the morning.
Initially 30 mg orally once daily in the morning; may increase by 10 mg or 20 mg weekly up to a maximum of 70 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 20-22 hours in steady state, allowing for once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal half-life of dextroamphetamine is approximately 10-12 hours in adults; clinical context: steady-state reached within 5 days.
Primarily renal elimination as unchanged drug and metabolites; approximately 65% of the dose is excreted in urine and 35% in feces via biliary secretion.
Renal: 96% (including 2.3% unchanged lisdexamfetamine, 17.2% amphetamine glucuronide, 3.8% amphetamine sulfate, 3.9% amphetamine N-acetyl, 1.9% amphetamine N-acetyl glucuronide, 0.3% other amphetamine metabolites, and 0.4% hippuric acid). Fecal: <1%.
Category C
Category C
CNS Stimulant (ADHD)
CNS Stimulant (ADHD)